In assessing the literature published to date regarding tumor cell expression of PD-L1 and outcomes in breast cancer (see Supplementary Table 1), it is important to consider several factors that vary between studies, including antibodies, scoring cut-off definitions, the composition of the cohorts and assessment methods. The gene discussed is CD274; the disease is neoplasm.